期刊
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE
卷 15, 期 -, 页码 -出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/17534666211016071
关键词
ILC2; interleukin-13; pulmonary fibrosis; RAGE; S100
资金
- American Heart Association [19POST34370078]
- Cystic Fibrosis Foundation [OURY19GO]
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease without effective therapies, leading to lung transplantation as the only viable option for survival. The receptor for advanced glycation endproducts (RAGE) plays a significant role in IPF, but its function remains incompletely understood.
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease in which most patients die within 3 years of diagnosis. With an unknown etiology, IPF results in progressive fibrosis of the lung parenchyma, diminishing normal lung function, which results in respiratory failure, and eventually, death. While few therapies are available to reduce disease progression, patients continue to advance toward respiratory failure, leaving lung transplantation the only viable option for survival. As incidence and mortality rates steadily increase, the need for novel therapeutics is imperative. The receptor for advanced glycation endproducts (RAGE) is most highly expressed in the lungs and plays a significant role in a number of chronic lung diseases. RAGE has long been linked to IPF; however, confounding data from both human and experimental studies have left an incomplete and perplexing story. This review examines the present understanding of the role of RAGE in human and experimental models of IPF, drawing parallels to recent advances in RAGE biology. Moreover, this review discusses the role of RAGE in lung injury response, type 2 immunity, and cellular senescence, and how such mechanisms may relate to RAGE as both a biomarker of disease progression and potential therapeutic target in IPF. The reviews of this paper are available via the supplemental material section.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据